VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
The business combination marks a significant milestone for VERAXA, which was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. By listing on Nasdaq, the company gains enhanced visibility and access to capital markets, which could accelerate the development of its next-generation antibody-based therapeutics.
According to the company, the BiTAC platform aims to address key limitations of current cancer immunotherapies, such as off-target toxicity and limited efficacy. The preclinical data presented at AACR 2026 highlighted the potential of their lead candidate to induce tumor regression while maintaining a favorable safety profile. This news matters because it represents progress in the development of more precise cancer treatments that could improve patient outcomes and reduce side effects.
The completion of the business combination also provides VERAXA with a stronger financial foundation. The $27.5 million senior secured note and the up to $50 million securities purchase agreement are expected to fund the advancement of their pipeline toward clinical trials. For the biotechnology industry, this underscores the continued trend of SPAC mergers as a pathway for emerging biotech companies to go public and secure funding for late-stage preclinical and early clinical work.
Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, was formed with a mission to revolutionize the healthcare sector through mergers, stock purchases, or business combinations. The transaction is a testament to the viability of SPACs in facilitating capital formation for innovative healthcare companies.
Investors and industry observers will be watching VERAXA's progress as it moves its BiTAC-TCE and BiTAC-ADC programs toward the clinic. The company's ability to translate preclinical promise into clinical success will be critical for its long-term viability and for validating its platform technology.
For more details, the full press release is available at https://ibn.fm/ka00j. Additional information about VERAXA Biotech can be found at www.veraxa.com.
